Drug Trial Radar · NCT02145130
Phase I Study for Autologous Dermal Substitutes and Dermo-epidermal Skin Substitutes for Treatment of Skin Defects
Last checked: Nov 19, 2026Latest source record: Sep 8, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
12
Actual
Start
May 2014
Primary completion
Mar 2021
Study completion Mar 2021
Sponsor
- Lead sponsor
- University of ZurichAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- University Hospital, Zürich
- First posted
- May 22, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 1 year, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is the evaluation of the safety of autologous tissue-engineered dermal substitutes "denovoDerm" (first arm) and dermo-epidermal skin substitutes "denovoSkin" (second arm) transplanted onto the wound bed in children and adults.
Conditions
- Burn Injury
- Soft Tissue Injury
- Skin Necrosis
- Scars
- Congenital Giant Nevus
- Skin Tumors
Interventions
denovoDermBiological
Transplantation of an autologous tissue-engineered dermal substitute, covered with autologous split-thickness skin
denovoSkinBiological
Transplantation of autologous tissue-engineered dermo-epidermal skin substitute, no additional coverage needed
Primary outcomes
What the sponsor says the trial is designed to measure.
- SafetyTime frame: denovoDerm: 4-6 days and 21 days after transplantation, denovoSkin 9-11 days and 21 days after transplantation
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
University Children's Hospital Zurich: denovoDerm
Zurich, Canton of Zurich, Switzerland
University Children's Hospital Zurich: denovoSkin
Zurich, Canton of Zurich, Switzerland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.